Nuclidium
Setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
$2.9m | Series A | ||
* | CHF2.4m | Grant | |
* | N/A | Early VC | |
| Total Funding | $5.1m | ||
Related Content
Recent News about Nuclidium
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.